Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.8
Journals
Current Oncology
Special Issues
Social Determinants of Health and Breast Cancer: Impacts on Diagnosis,...
share announcement

Social Determinants of Health and Breast Cancer: Impacts on Diagnosis, Treatment, and Outcomes

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 480

Special Issue Editors

Dr. Charlotte Yong-Hing

E-Mail Website
Guest Editor
Department of Radiology, University of British Columbia, Vancouver, BC, Canada
Interests: breast imaging; radiology equity; diversity; breast cancer screening; healthcare policy
Dr. Nathalie LeVasseur

E-Mail Website
Guest Editor
BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC V5Z 4E6, Canada
Interests: medical oncology; breast cancer; cancer biomarkers; tumor biology; translational medicine

Special Issue Information

Dear Colleagues,

The Special Issue of Current Oncology, "Social Determinants of Health and Breast Cancer: Impacts on Diagnosis, Treatment, and Outcomes", aims to explore the complex interplay between socioeconomic factors and breast cancer care.

This issue will address how determinants such as race, ethnicity, income, education, and geographic location affect breast cancer screening, diagnosis, treatment options, and outcomes. By examining these disparities, the issue seeks to highlight barriers to equitable healthcare access and quality. 

Contributions from a multidisciplinary perspective, including public health, radiology, oncology, and healthcare policy, will provide insights into strategies for addressing these inequities and improving outcomes for marginalized populations. 

In this Special Issue, original research articles and reviews are welcome. 

I look forward to receiving your contributions.

Dr. Charlotte Yong-Hing
Dr. Nathalie LeVasseur
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • social determinants of health
  • breast cancer disparities
  • healthcare access
  • health equity
  • screening and diagnosis
  • treatment outcomes
  • socioeconomic factors
  • racial and ethnic disparities
  • healthcare policy
  • marginalized populations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 750 KiB  
Article
First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
by Guillermo Valencia, Patricia Rioja, Miguel Chirito, Olenka Peralta, Jorge Sánchez, Connie Rabanal, Raúl Mantilla, Zaida Morante, Hugo Fuentes, Carlos Castaneda, Tatiana Vidaurre, Cristian Pacheco, Silvia Neciosup and Henry L. Gomez
Curr. Oncol. 2024, 31(12), 7890-7902; https://doi.org/10.3390/curroncol31120581 - 9 Dec 2024
Viewed by 330
Abstract
Advanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our [...] Read more.
Advanced breast cancer is an incurable disease, with a median overall survival of 3 years, including in countries without access problems. Although chemotherapy is reserved in some cases, it is still used in many countries as a first-line therapy. The aim of our study is to evaluate the first-line treatment choices and the factors that influence therapeutic decisions. A retrospective analysis was conducted of hormone receptor (+)/HER2 (−) advanced breast cancer patients classified into three groups according to the first-line and second-line treatment received: endocrine therapy–chemotherapy, endocrine therapy–endocrine therapy and chemotherapy–endocrine therapy. Additionally, we explored the overall survival of sequencing therapy groups. First-line chemotherapy was chosen in 34% of patients. Also, around 60% of our patients met the “aggressive disease” criteria from the RIGHT Choice trial, justifying the use of chemotherapy in a population with poor prognosis. Furthermore, de novo and progressive disease were prognostic factors that influenced the use of chemotherapy as a first-line treatment. Regarding overall survival, the sequencing treatment groups in this trial saw an increase in survival compared with patients of the MONALEESA trials (endocrine therapy alone arms). No significant differences in progression-free survival or overall survival were found in the treatment sequencing groups. There was a higher use of chemotherapy as a first-line therapy, with de novo and “aggressive disease” criteria being the main factors to influence the decision. Full article
(This article belongs to the Special Issue Social Determinants of Health and Breast Cancer: Impacts on Diagnosis, Treatment, and Outcomes)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop